Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention

Cardiology

Volumn 104, Issue 2, 2005, Pages 97-100

  Cho, Leslie ^a   Lewis, Bruce E ^a   Steen, Lowell H ^a   Leya, Ferdinand S ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Coronary artery disease; Diabetes; Stents; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; AGED; ANALYSIS; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; CORONARY STENT; DEATH; DIABETES MELLITUS; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PATIENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; CORONARY CIRCULATION; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; STENTS; SURVIVAL RATE; THIAZOLIDINEDIONES;

EID: 23944482409     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086748     Document Type: Article

References (12)

1. Marso SP: Optimizing the diabetic formulary: Beyond aspirin and insulin. J Am Coll Cardiol 2002;40:652-661.
2. Thomas J, Taylor K: Effects of troglitazone on lipoprotein subclasses in patients who are insulin resistant. Diabetes 2001;50:A455.
3. McTernan P, Eggo M, Smith S, Barnett AH: Rosiglitazone inhibits the insulin mediated increase in PAI-1 secretion in human subcutaneous adipocytes. Diabetes 2001;50:A275.
4. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W: Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003;107:1954-1957.
5. Marx N, Froehlich, Siam L, Ittner J, Wierse G, Schmidt A, Scharnagl H, Hombach V, Koenig W: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003;23:283-288.
6. Tontonoz P, Nagy L: Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: Implications for cardiovascular disease. Curr Opin Lipidol 1999;10:485-490.
7. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
8. Hannan K, Dilley R, de Dios S, Little P: Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol 2003;23:762-768.
9. Walczak R, Tontonoz P: PPARadigms and PPARadoxes: Expanding roles for PPAR gamma in the control of lipid metabolism. J Lipid Res 2002;43:177-186.
10. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:1529-1535.
11. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Morioka S, Akasada T, Yoshida K: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002;89:318-322.
12. de Dios S, Bruemmer D, Dilley R, Ivey M, Jennings G, Law RE, Little P: Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003;107:2548-2550.